Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LOXO-338 |
| Synonyms | |
| Therapy Description |
LOXO-338 inhibits BCL2, potentially leading to inhibition of tumor cell proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1258). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LOXO-338 | LOXO338|LOXO 338|LY3847429|FCN338|FCN-338 | BCL2 inhibitor 29 | LOXO-338 inhibits BCL2, potentially leading to inhibition of tumor cell proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1258). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05024045 | Phase I | LOXO-338 + Pirtobrutinib LOXO-338 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | Active, not recruiting | USA | POL | ITA | FRA | 0 |
| NCT02632994 | Expanded access | LY3023414 LOXO-338 LY2503029 LOXO-260 | Master Rollover Protocol for Continued Safety Assessment of Study Drug | Available | USA | 0 |